You might also like
Biogen Inc. is a biotechnology company dedicated to discovering, developing, and delivering innovative therapies for serious neurological and neurodegenerative diseases, operating as a single segment company . The company offers a range of products, including treatments for multiple sclerosis (MS), rare diseases, and biosimilars . Biogen also engages in collaborations and partnerships to expand its pipeline and market presence, such as with Eisai for LEQEMBI and Sage Therapeutics for ZURZUVAE .
- Multiple Sclerosis (MS) Treatments - Provides a comprehensive suite of therapies for MS, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.
- Rare Disease Treatments - Offers specialized treatments for rare diseases, featuring products like SPINRAZA, QALSODY, and SKYCLARYS.
- Biosimilars - Develops and markets biosimilar products, including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
- Given surveys indicating a less favorable view among neurologists and Alzheimer's specialists regarding LEQEMBI's risk-benefit and cost-benefit ratios, and some questioning the amyloid hypothesis, how is Biogen addressing these concerns, and are you experiencing any pushback from healthcare providers who were initially ready to prescribe LEQEMBI?
- With the EMA's negative opinion on LEQEMBI, what specific steps is Biogen taking to reverse this decision, and what is your confidence level that the decision can be overturned through reexamination, considering the issues raised by the EMA?
- For SKYCLARYS, can you provide more details on patient discontinuation rates and how they compare to clinical trial data, and what strategies are you implementing to ensure patient adherence, especially among those who may not see immediate efficacy?
- After opting out of the Angelman syndrome program with Ionis, how has your approach to evaluating partnerships and collaborations evolved, and what specific aspects of potential programs are you now scrutinizing more closely before committing resources?
- Given competitive pressures on your core products and the need for successful new launches, what gives you confidence that 2023 will be the trough year for earnings, and what are the key factors that need to play out for Biogen to achieve sustainable growth through the end of the decade?
Competitors mentioned in the company's latest 10K filing.
- Sanofi Genzyme: Competitor for AUBAGIO (teriflunomide) in the MS market .
- Banner Life Sciences: Competitor for BAFIERTAM (monomethyl fumarate) in the MS market .
- Bayer Group: Competitor for BETASERON/BETAFERON (interferon-beta-1b) in the MS market .
- TG Therapeutics, Inc.: Competitor for BRIUMVI (ublituximab-xiiy) in the MS market .
- Teva Pharmaceuticals Industries Ltd.: Competitor for COPAXONE (glatiramer acetate) in the MS market .
- Novartis AG: Competitor for EXTAVIA (interferon-beta-1b), GILENYA (fingolimod), KESIMPTA (ofatumumab), and MAYZENT (siponimod) in the MS market .
- Sandoz, a division of Novartis AG: Competitor for GLATOPA (glatiramer acetate) and TYRUKO (natalizumab-sztn) in the MS market .
- Genentech: Competitor for OCREVUS (ocrelizumab) in the MS market .
- Janssen Pharmaceutical Companies of Johnson & Johnson: Competitor for PONVORY (ponesimod) in the MS market .
- EMD Serono: Competitor for REBIF (interferon-beta-1) and MAVENCLAD (cladribine) in the MS market .
- Bristol Myers Squibb Company: Competitor for ZEPOSIA (ozanimod) in the MS market .
- TG Therapeutics, Inc.: Competitor for BRIUMVI (ublituximab-xiiy) in the MS market .
- Samsung Bioepis: Partner for biosimilars BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ, which compete with ENBREL, HUMIRA, REMICADE, and LUCENTIS, respectively .
- Genentech: Competitor for RITUXAN, RITUXAN HYCELA, GAZYVA, and LUNSUMIO in oncology and rheumatoid arthritis markets .
- Teva Pharmaceuticals Industries Ltd.: Competitor for COPAXONE (glatiramer acetate) in the MS market .
- Novartis AG: Competitor for EXTAVIA (interferon-beta-1b), GILENYA (fingolimod), KESIMPTA (ofatumumab), and MAYZENT (siponimod) in the MS market .
- Sandoz, a division of Novartis AG: Competitor for GLATOPA (glatiramer acetate) and TYRUKO (natalizumab-sztn) in the MS market .
- Genentech: Competitor for OCREVUS (ocrelizumab) in the MS market .
- Janssen Pharmaceutical Companies of Johnson & Johnson: Competitor for PONVORY (ponesimod) in the MS market .
- EMD Serono: Competitor for REBIF (interferon-beta-1) and MAVENCLAD (cladribine) in the MS market .
- Bristol Myers Squibb Company: Competitor for ZEPOSIA (ozanimod) in the MS market .
Customer | Relationship | Segment | Details |
---|---|---|---|
Major Wholesaler #1 | Wholesale distribution partner | All | In 2023, accounted for approx. 27.0% of gross product revenue, 2022: 26.8%, 2021: 28.8%.Accounts receivable: approx. 24.6% as of Dec. 31, 2023And 22.7% as of Dec. 31, 2022. |
Major Wholesaler #2 | Wholesale distribution partner | All | In 2023, accounted for approx. 9.9% of gross product revenue, 2022: 11.1%, 2021: 10.1%.Accounts receivable: approx. 11.6% as of Dec. 31, 2023And 10.9% as of Dec. 31, 2022. |
Recent developments and announcements about BIIB.
Corporate Leadership
CFO Change
Michael McDonnell, the current Chief Financial Officer (CFO) of Biogen Inc., will retire on March 1, 2025. Robin Kramer, the current Chief Accounting Officer, has been appointed as the new CFO effective upon his retirement.
Leadership Change
Michael McDonnell is retiring as Chief Financial Officer of Biogen Inc. on March 1, 2025. Robin Kramer will step up as the new Chief Financial Officer. Sean Godbout has been appointed as Vice President, Chief Accounting Officer & Global Corporate Controller, effective March 1, 2025, replacing Robin Kramer in that role.
CFO Change
Michael McDonnell, the Chief Financial Officer of Biogen Inc., has announced his retirement effective February 28, 2025. Robin Kramer, currently the Chief Accounting Officer, will succeed him as CFO .